Medical supply and device firm Covidien (NYSE:COV) reported second quarter results late in April 2012 and modest sales growth. It hopes that by spinning off a stodgier division to investors it will be able to boost its total growth trends going forward, and this could help it bridge its current valuation discount with a number of purer-play rivals.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

First Quarter Recap
Net sales advanced 5% and reached nearly $3 billion. Medical device (instruments, soft tissue repair products, airway and ventilation devices) sales increased 7% to $2 billion, or two thirds of the total top line. United States growth of 8% exceeded international growth, which grew 7%. Pharmaceutical sales (specialty pharmaceutical drugs and ingredients) were the next largest category and grew 5% to make up just over 17% of the top line. U.S. growth of 6% again exceeded international growth of 2%. The remaining segment is medical supplies (nursing, medical care products), which was flat and accounted for the remaining roughly 15% of total sales.

Lower product costs and restructuring charges helped send operating income up 7% to almost $1.3 billion. This represented a healthy operating margin of 21.3% of total sales. A drop in tax expenses further boosted net income to $991 million for growth of 12.4% from last year's first quarter. Earnings rose 15.3% to $2.04, due to share buybacks.

SEE: A Breakdown Of Stock Buybacks

Outlook and Valuation
Analysts project full year 2012 sales of nearly 3% and total sales of $11.9 billion. The consensus earnings projection currently stands at $4.30 per share and would represent annual growth above 31%. At the current share price of $56, the forward P/E is 12. This is slightly below Becton Dickinson's (NYSE:BDX) forward P/E of 12.5 and C.R. Bard's (NYSE:BCR) multiple of 14.

The Bottom Line
Since its spinoff from Tyco (NYSE:TYC) in 2007, Covidien has managed to boost sales 30% and profits at a similar level after posting a loss the year it was spun out. Since that time, its stock is up around 20% to lead the pack, along with Bard. It also beats the overall market return, which is roughly down 10%.

Despite these decent trends, management has chosen to shake things up and will be spinning off the pharmaceutical unit to investors in yet another spinoff. The announcement was made on Dec. 15, 2011 when pharma was estimated to log $2 billion in annual sales. It will be a top 10 player in the generic drug space and is also a large producer of bulk acetaminophen that is used in pain medication. It should free up Covidien to focus on growing its medical businesses and leave pharma to compete in the drug space along with larger rival Teva Pharmaceutical (Nasdaq:TEVA).

SEE: 5 Must-Have Metrics For Value Investors

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Ryan C. Fuhrmann did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  6. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  7. Professionals

    What to do During a Market Correction

    The market has what? Here's what you should consider rather than panicking.
  8. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  9. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  10. Professionals

    Tips for Helping Clients Though Market Corrections

    When the stock market sees a steep drop, clients are bound to get anxious. Here are some tips for talking them off the ledge.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!